Metoclopramide in the treatment of diabetic gastroparesis

Expert Review of Endocrinology and Metabolism

Volumn 5, Issue 5, 2010, Pages 653-662

  Lee, Allen ^a   Kuo, Braden ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

diabetes mellitus; gastroparesis; metoclopramide; tardive dyskinesia

Indexed keywords

METOCLOPRAMIDE;

AKITHISIA; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DISEASE ASSOCIATION; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; HUMAN; HYPERPROLACTINEMIA; LETHARGY; PARKINSONISM; POSTOPERATIVE VOMITING; PRIORITY JOURNAL; REVIEW; STOMACH PARESIS; TARDIVE DYSKINESIA; VOMITING;

EID: 77956846919     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.10.41     Document Type: Review

References (80)

1. Stanghellini V, Tosetti C, Paternico A et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 110(4), 1036-1042 (1996).
2. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig. Dis. Sci. 43(11), 2398-2404 (1998).
3. Kristensson K, Nordborg C, Olsson Y, Sourander P. Changes in the vagus nerve in diabetes mellitus. Acta Pathol. Microbiol. Scand. 79(6), 684-685 (1971).
4. Merio R, Festa A, Bergmann H et al. Slow gastric emptying in Type I diabetes: relation to autonomic and peripheral neuropathy, blood glucose, and glycemic control. Diabetes Care 20(3), 419-423 (1997).
5. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 115(3), 387-397 (2007).
6. Rothstein RD. Gastrointestinal motility disorders in diabetes mellitus. Am. J. Gastroenterol. 85(7), 782-785 (1990).
7. Sanger GJ, Lee K. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders. Nat. Rev. Drug Discov. 7(3), 241-254 (2008).
8. Forster J, Damjanov I, Lin Z, Sarosiek I, Wetzel P, McCallum R. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J. Gastrointest. Surg. 9(1), 102-108 (2005).
9. Parkman HP, Camilleri M, Farrugia G et al. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol. Motil. 22(2), 113-133 (2010).
10. Hasler WL. Gastroparesis: symptoms, evaluation, and treatment. Gastroenterol. Clin. North Am. 36, 619-647 (2007).
11. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 37(6), 543-551 (1994).
12. Kong MF, Horowitz M. Gastric emptying in diabetes mellitus: relationship to blood-glucose control. Clin. Geriatr. Med. 15(2), 321-338 (1999).
13. Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann. Intern. Med. 96(4), 444-446 (1982).
14. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment. Pharmacol. Ther. 31(1), 11-19 (2010).
15. Justin-Besancon L, Laville C. Antiemetic action of metoclopramide with respect to apomorphine and hydergine]. CR Seances Soc. Biol. Fil. 158, 723-727 (1964).
16. Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J. Am. Pharm. Assoc. (2003) 44(6), 661-665 (2004).
17. Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab. Dispos. 30(3), 336-343 (2002).
18. Bateman DN. Clinical pharmacokinetics of metoclopramide. Clin. Pharmacokinet. 8(6), 523-529 (1983).
19. Magueur E, Hagege H, Attali P, Singlas E, Etienne JP, Taburet AM. Pharmacokinetics of metoclopramide in patients with liver cirrhosis. Br. J. Clin. Pharmacol. 31(2), 185-187 (1991).
20. Bateman DN, Gokal R, Dodd TR, Blain PG. The pharmacokinetics of single doses of metoclopramide in renal failure. Eur. J. Clin. Pharmacol. 19(6), 437-441 (1981).
21. Muller DJ, Shinkai T, De Luca V, Kennedy JL. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J. 4(2), 77-87 (2004).
22. Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab. Dispos. 27(9), 1078-1084 (1999).
23. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. Br. J. Med. 320(7240), 987-990 (2000).
24. Vella A, Lee JS, Camilleri M et al. Effects of pramlintide, an amylin analogue, on gastric emptying in Type 1 and 2 diabetes mellitus. Neurogastroenterol. Motil. 14(2), 123-131 (2002).
25. Ratner RE, Dickey, R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet. Med. 21(11), 1204-1212 (2004).
26. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. 143(8), 559-569 (2005).
27. Talley SJ, Bytzer P, Hammer J, Young L, Jones M, Horowitz M. Psychological distress is linked to gastrointestinal symptoms in diabetes mellitus. Am. J. Gastroenterol. 96(4), 1033-1038 (2001). (Pubitemid 32319133)
28. Yu J, Paine MJ, Marechal JD et al. In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide. Drug Metab. Dispos. 34(8), 1386-1392 (2006).
29. Valenzuela JE, Dooley C. Dopamine antagonists in the upper gastrointestinal tract. Scand. J. Gastroenterol. Suppl. 96, 127-136 (1984).
30. Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment. Pharmacol. Ther. 19(4), 379-390 (2004).
31. Fernandez AG, Massingham R. Peripheral receptor populations involved in the regulation of gastrointestinal motility and the pharmacological actions of metoclopramide-like drugs. Life Sci. 36(1), 1-14 (1985).
32. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann. Intern. Med. 98(1), 86-95 (1983).
33. Clarke DE, Craig DA, Fozard JR. The 5-HT4 receptor: naughty, but nice. Trends Pharmacol. Sci. 10(10), 385-386 (1989).
34. Dumitrascu DL, Ungureanu O, Verzea D, Pascu O. The effect of metoclopramide on antral emptying of a semisolid meal in patients with functional dyspepsia. A randomized placebo controlled sonographic study. Rom. J. Intern. Med. 36(1-2), 97-104 (1998).
35. Kishibayashi N, Karasawa A. Stimulating effects of KW-5092, a novel gastroprokinetic agent, on the gastric emptying, small intestinal propulsion and colonic propulsion in rats. Jpn J. Pharmacol. 67(1), 45-50 (1995).
36. Lang IM, Sarna SK, Condon RE. Gastrointestinal motor correlates of vomiting in the dog: quantification and characterization as an independent phenomenon. Gastroenterology 90(1), 40-47 (1986).
37. Mitchelson F. Pharmacological agents affecting emesis. A review (part I). Drugs 43(3), 295-315 (1992).
38. Mahajan HS, Gattani S. In situ gels of metoclopramide hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits. Drug Deliv. 17(1), 19-27 (2010).
39. McCallum RW, Valenzuela G, Polepalle S, Spyker D. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J. Pharmacol. Exp. Ther. 258(1), 136-142 (1991).
40. Brownlee M, Kroopf SS. Letter: metoclopramide for gastroparesis diabeticorum. N. Engl. J. Med. 291(23), 1257-1258 (1974).
41. Longstreth GF, Malagelada JR, Kelly KA. Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Ann. Intern. Med. 86(2), 195-196 (1977).
42. Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig. Dis. Sci. 24(9), 662-666 (1979).
43. McCallum RW, Ricci DA, Rakatansky H et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 6(5), 463-467 (1983).
44. Loo FD, Palmer DW, Soergel KH, Kalbfleisch JH, Wood CM. Gastric emptying in patients with diabetes mellitus. Gastroenterology 86(3), 485-494 (1984).
45. Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J. Clin. Gastroenterol. 7(1), 25-32 (1985).
46. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 16(11), 1511-1514 (1993).
47. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am. J. Gastroenterol. 94(5), 1230-1234 (1999).
48. Lata PF, Pigarelli DL. Chronic metoclopramide therapy for diabetic gastroparesis. Ann. Pharmacother. 37(1), 122-126 (2003).
49. Schade RR, Dugas MC, Lhotsky DM, Gavaler JS, Van Thiel DH. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig. Dis. Sci. 30(1), 10-15 (1985).
50. Chen JD, Pan J, McCallum RW. Clinical significance of gastric myoelectrical dysrhythmias. Dig. Dis. 13(5), 275-290 (1995).
51. Bradette M, Pare P, Douville P, Morin A. Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone. Dig. Dis. Sci. 36(1), 52-58 (1991).
52. Banner SE, Sanger GJ. Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity. Br. J. Pharmacol. 114(2), 558-562 (1995).
53. Rowbotham DJ, Bamber PA, Nimmo WS. Comparison of the effect of cisapride and metoclopramide on morphine-induced delay in gastric emptying. Br. J. Clin. Pharmacol. 26(6), 741-746 (1988).
54. de Caestecker JS, Ewing DJ, Tothill P, Clarke BF, Heading RC. Evaluation of oral cisapride and metoclopramide in diabetic autonomic neuropathy: an eight-week double-blind crossover study. Aliment. Pharmacol. Ther. 3(1), 69-81 (1989).
55. Suchitra AD, Dkhar SA, Shewade DG, Shashindran CH. Relative efficacy of some prokinetic drugs in morphine-induced gastrointestinal transit delay in mice. World J. Gastroenterol. 9(4), 779-783 (2003).
56. Kelly J, Alheid GF, McDermott L, Halaris A, Grossman SP. Behavioral and biochemical effects of knife cuts that preferentially interrupt principal afferent and efferent connections of the striatum in the rat. Pharmacol. Biochem. Behav. 6(1), 31-45 (1977).
57. Quenzer LF, Galli CL, Neff NH. Activation of the nigrostriatal dopaminergic pathway by injection of cholera enterotoxin into the substantia nigra. Science 195(4273), 78-80 (1977).
58. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev. 22(6), 724-763 (2001).
59. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 127(5), 1592-1622 (2004).
60. Jolliet P, Nion S, Allain-Veyrac G. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared with domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood- brain barrier. Pharmacol. Res. 56(1), 11-17 (2007).
61. Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch. Intern. Med. 149(11), 2486-2492 (1989).
62. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement - a review of the clinical benefits and medicolegal risks of metoclopramide. Nat. Clin. Pract. Gastroenterol. Hepatol. 3(3), 138-148 (2006).
63. van der Padt A, van Schaik RH, Sonneveld P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth. J. Med. 64(5), 160-162 (2006).
64. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br. Med. J. (Clin. Res. Ed.) 291(6500), 930-932 (1985).
65. Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch. Intern. Med. 153(12), 1469-1475 (1993).
66. McCallum RW, Ippoliti AF, Cooney C, Sturdevant RA. A controlled trial of metoclopramide in symptomatic gastroesophageal reflux. N. Engl. J. Med. 296(7), 354-357 (1977).
67. Jungmann E, Schoffling K. Akathisia and metoclopramide. Lancet 2(8291), 221 (1982).
68. Regan LA, Hoffman RS, Nelson LS. Slower infusion of metoclopramide decreases the rate of akathisia. Am. J. Emerg. Med. 27(4), 475-480 (2009).
69. Avorn J, Gurwitz JH, Bohn RL, Mogun H, Monane M, Walker A. Increased incidence of levodopa therapy following metoclopramide use. JAMA 274(22), 1780-1782 (1995).
70. Abell TL, Bernstein RK, Cutts T et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol. Motil. 18(4), 263-283 (2006).
71. Wiholm BE, Mortimer O, Boethius G, Haggstrom JE. Tardive dyskinesia associated with metoclopramide. Br. Med. J. (Clin. Res. Ed.) 288(6416), 545-547 (1984).
72. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J. Clin. Pharmacol. 48(3), 379-384 (2008).
73. Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV. Metoclopramide and tardive dyskinesia. Biol. Psychiatry 36(9), 630-632 (1994).
74. Sewell DD, Jeste DV. Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. Arch. Fam. Med. 1(2), 271-278 (1992).
75. Cooper BT, Mountford RA, McKee C. Galactorrhoea, hyperprolactinaemia, and pituitary adenoma presenting during metoclopramide therapy. Postgrad. Med. J. 58(679), 314-315 (1982).
76. Maddern GJ. Galactorrhoea due to domperidone. Med. J. Aust. 2(11), 539-540 (1983).
77. Kaufman JM, Elewaut A, Vermeulen A. Effect of domperidone on prolactin (PRL) and thyrotrophin (TSH) secretion. Arch. Int. Pharmacodyn. Ther. 254(2), 293-303 (1981).
78. Corazza GR, Biagi F, Albano O et al. Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial. Ital. J. Gastroenterol. 28(6), 317-323 (1996).
79. Hyett B, Martinez FJ, Gill BM et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 137(2), 445-452 (2009).
80. Jung HK, Choung RS, Locke GR 3rd et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 136(4), 1225-1233 (2009).